CAS 156251-11-5

L-Valine,L-alanyl-L-alanylglycyl-L-isoleucylglycyl-L-isoleucyl-L-leucyl-L-threonyl-

Description:

L-Valine, L-alanyl-L-alanylglycyl-L-isoleucylglycyl-L-isoleucyl-L-leucyl-L-threonyl, identified by the CAS number 156251-11-5, is a complex peptide composed of multiple amino acids. This substance is characterized by its structure, which includes branched-chain amino acids such as valine and isoleucine, as well as other amino acids like alanine, glycine, leucine, and threonine. Peptides like this one often exhibit specific biological activities, including roles in protein synthesis, cellular signaling, and metabolic processes. The presence of multiple amino acids suggests potential applications in biochemistry and pharmaceuticals, particularly in the development of peptide-based therapeutics or nutritional supplements. Additionally, the sequence and composition of the amino acids can influence the peptide's solubility, stability, and interaction with biological systems. Overall, this compound represents a significant area of interest in both research and applied sciences, particularly in understanding protein structure and function.

Formula: C₃₇H₆₇N₉O₁₁

Synonyms:

• Melan A

MART-1 (27-35) (human)

CAS: 156251-11-5

Bachem ID: 4095854.

Formula: C₃₇H₆₇N₉O₁₁

Color and Shape: White Lyophilisate

Molecular weight: 813.99

Ref: 01-4095854

MART-1 (27-35) (human)

CAS: 156251-11-5

Tumour antigens recognised by cytotoxic T cells (CTLs) are a keen area of research to develop antigen-specific cancer therapies. However, hurdles are weak immunogenicity and high rates of degradation in vivo. In the search for a melanoma vaccine, the human tumour antigen Melan-A/MART-1 (27-35) has been used as a model to design peptides with improved characteristics for use in anti-tumour vaccines. The epitope can induce the production of melanoma-specific CD8+ T-cell responses. It has been included in melanoma antigen peptide vaccines, clinical trial data suggest that MART-1 (27-35) in human systems alongside other epitopes does affect the cellular and humoral responses, but much more work is required with this peptide to optimise it for clinical efficacy against melanoma.An alternate route that is possible but less studied is using MART-1 (27-35) to isolate CD8(+) T-cell clones with greater recognition for the epitope due to the contact with the T-cell receptor. This suggests melanomas could be targeted by optimising the T-cell receptor-peptide recognition of the T-cell repertoire by enhancing antigen targeting.

Formula: C₃₇H₆₇N₉O₁₁

Molecular weight: 813.98 g/mol

Ref: 3D-CRB1000727

MART-1 (27-35) (human)

CAS: 156251-11-5

Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool

Formula: C₃₇H₆₇N₉O₁₁

Molecular weight: 814 g/mol

Ref: 3D-PP50716

MART-1 (27-35) (human) trifluoroacetate salt

Controlled Product

CAS: 156251-11-5

Please enquire for more information about MART-1 (27-35) (human) trifluoroacetate salt including the price, delivery time and more detailed product information at the technical inquiry form on this page

Formula: C₃₇H₆₇N₉O₁₁

Purity: Min. 95%

Molecular weight: 813.98 g/mol

Ref: 3D-FM110241